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Abstract
Gemcitabine is used to treat several cancers including lung cancer. However, tumor cells often escape
gemcitabine-induced cell death via various mechanisms, which include modulating bcl-2 family members and NF-
B activation. We previously reported that the C-terminal region of Bfl-1 fused with GFP (BC) is sufficient to induce
apoptosis in 293T cells. In the present study, we investigated the anti-tumor effect of combined BC gene therapy
and gemcitabine chemotherapy in vitro and in vivo using non-small cell lung cancer cell lines and a xenograft
model. Cell lines were resistant to low dose gemcitabine (4-40 ng/ml), which induced NF-B activation and
concomitant up-regulation of Bfl-1 (an NF-B-regulated anti-apoptotic protein). BC induced the apoptosis of A549
and H157 cells with caspase-3 activation. Furthermore, co-treatment with BC and low dose gemcitabine
synergistically and efficiently induced mitochondria-mediated apoptosis in these cells. When administered alone or
with low dose gemcitabine, BC suppressed NF-B activity, inhibited the nuclear translocation of p65/relA, and
down-regulated Bfl-1 expression. Furthermore, direct suppression of Bfl-1 by RNA interference sensitized cells to
gemcitabine-induced cell death, suggesting that Bfl-1 importantly regulates lung cancer cell sensitivity to
gemcitabine. BC and gemcitabine co-treatment also showed a strong anti-tumor effect in a nude mouse/A549
xenograft model. These results suggest that lung cancer cells become resistant to gemcitabine via NF-B activation
and the subsequent overexpression of Bfl-1, and that BC, which has both pro-apoptotic and NF-B inhibitory
effects, could be harnessed as a gene therapy to complement gemcitabine chemotherapy in non-small cell lung
cancer.
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Introduction
Lung cancer remains a leading cause of cancer-related
death [1] despite the introduction of several types of
cytotoxic agents. In non-small cell lung cancer
(NSCLC), chemotherapy often achieves limited clinical
improvements due to acquired drug resistance and
intolerable toxicities. Gemcitabine (difluorodeoxycytidine
hydrochloride, dFdC) is a deoxycytidine analogue that is
converted in vivo into the active metabolites, difluoro-
deoxycytidine di- and triphosphate (dFdCDP, dFdCTP).
DFdCDP acts by inhibiting ribonucleotide reductase,
whereas dFdCTP is incorporated into DNA and pre-
vents DNA synthesis, thereby inducing apoptosis. Gem-
citabine has been approved by the Food and Drug
Administration (FDA) as a treatment for advanced and
metastatic pancreatic cancer, ovarian cancer, breast can-
cer, and NSCLC, alone or in combination with other
drugs http://www.cancer.gov/cancertopics/druginfo/gem-
citabinehydrochloride. Clinical trials have demonstrated
that gemcitabine prolongs survival and improves the
quality of life of advanced NSCLC patients [2]. In fact,
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tive agents for treating NSCLC. Previous studies have
concluded that when used as a single agent, gemcitabine
consistently yields response rates exceeding 20%.
Furthermore, preclinical data indicate that when used
with platinum compounds, such as, cisplatin or carbo-
platin, gemcitabine has synergistic anti-tumor effects
[3,4].
However, gemcitabine often fails to achieve adequate
disease control due to intrinsic or acquired resistance of
tumor cells. The following are representative examples
of putative resistance mechanisms; NF-B and PI3K/Akt
pathway activation in pancreatic and breast cancer [5,6]
the up-regulation of anti-apoptotic Bcl-2 protein in pan-
creatic cancer [7,8] the deficiency of human equilibrate
nucleoside transporter 1 in NSCLC [9]and alterations of
gemcitabine metabolizing enzymes [10-13]. Many of
these chemo-resistant mechanisms involve interrupting
the apoptotic pathway [14]. In particular, increased
expression of anti-apoptotic bcl-2 family proteins stabi-
lizes the mitochondrial membrane, and thus, elevates
the apoptotic threshold. Accordingly, the suppression of
Bcl-2 using siRNA (small interfering RNA) restores
gemcitabine sensitivity in pancreatic cancer cells [8].
The anti-apoptotic effects of chemotherapy-induced NF-
B activation are mediated by a series of molecules
regulated by NF-B, and by inhibiting NF-Bt u m o r
cells can be sensitized to chemotherapeutic agents, such
as, gemcitabine [15-17]. For example, the inhibition of
NF-B by bortezomib (a proteasome inhibitor) sensi-
tized NSCLC to gemcitabine-induced apoptosis, and the
silencing of the NF-Bp 6 5 / r e l As u b u n i tw i t hs i R N A
increased the effectiveness of gemcitabine in a subset of
pancreatic cancer cells [18,19]. In addition, resistance to
gemcitabine may be overcome by using in combination
with cytotoxic agents with different modes of action [7].
Of note, combined gene therapy has been proposed as a
means of overcoming resistance to chemotherapy, as
demonstrated by enhanced chemosensitivity via the tar-
geted down-regulation of anti-apoptotic Bcl-2 and Bcl-
xL [12,20-22]
Recently, Bfl-1 was found to be a direct transcrip-
tional target of NF-B [23-25]. Bfl-1 interacts and
sequestrates the pro-apoptotic molecules, Bid and Bim,
and thereby suppresses apoptosis and inhibits cyto-
c h r o m ecr e l e a s ef r o mm i t o c h o n d r i a[ 2 6 , 2 7 ] .W ep r e -
viously observed high levels of Bfl-1 mRNA in blood,
lung, and stomach cancer cell lines [28], and separately
reported that a Bfl-1/green fluorescent protein (GFP)
adduct induces caspase activation and disrupts mito-
chondrial permeability in 293T cells. Furthermore, the
domain responsible for this apoptotic function of Bfl-1
fused with GFP was mapped to 20 amino acids in its C-
terminal region [17]. Therefore, we hypothesized that
gene therapy based on the expression of a protein con-
taining the C-terminal of Bfl-1 and GFP (BC) might
sensitize cancer cells to gemcitabine.
In the present study, we demonstrate that low dose
gemcitabine activates NF-B and subsequently up-regu-
lates Bfl-1 in NSCLC cells, which has been suggested to
be a major mechanism of resistance to gemcitabine. We
found that BC gene therapy inhibited NF-B activity
and decreased Bfl-1 expression, and restored sensitivity
to gemcitabine. Furthermore, combined BC and gemci-
tabine therapy effectively suppressed tumor growth in a
xenograft model. Accordingly, our findings suggest that
combined BC gene therapy and gemcitabine chemother-
apy offers a potential means of overcoming resistance to
gemcitabine chemotherapy in NSCLC.
Materials and methods
Cell lines and reagent
HEK 293 (human embryonic kidney fibroblasts, ATCC
CRL-1573™, passage-13) was grown in DMEM supple-
mented with 10% FBS (Invitrogen, Groningen, The
Netherlands). Human NSCLC cell lines, A549 (adeno-
carcinoma, ATCC CCL-185, passage-23), H460 (large-
cell carcinoma, ATCC HTB-177, passage-7), H157
(squamous cell carcinoma, ATCC CRL-5802, passage-
18) and PC-9 (adenocarcinoma, was kindly provided by
Prof. Tae-You Kim, Seoul National University College of
Medicine, Seoul, Korea) were maintained in RPMI1640
containing 10% FBS. All cells were verified by morphol-
ogy, growth curve analysis and tested for Mycoplasma.
All cell lines except for PC-9 were obtained from and
characterized by the American Type Culture Collection
(ATCC). No further authentication was done by the
authors. Gemcitabine was purchased from Eli Lilly (Sur-
esnes, France).
Recombinant adenovirus with Tet-off system
The cDNA fragments of human Bfl-1 corresponding to
amino acids 147-175 and mouse Bax were amplified by
PCR and subcloned into pEGFPC1 vector (Clontech,
Palo Alto, CA) to generate GFP-Bfl-1-C-terminal (BC)
and GFP-Bax, respectively, as previously described
[17,29]. Bfl-1-C-terminal was fused with multi-cloning
site of pEGFPC1 (not involve GFP) for external charged
residues, and subcloned into pcDNA vector to generated
pMBC. GFP- Bfl-1-C-terminal (BC), GFP, and Bfl-1
were subcloned into the NheI/SalI site of pTRE shuttle
vector (Clontech) to generate pTRE-BC, pTRE-GFP, and
pTRE-Bfl-1. GFP-Bax (gBax) was subcloned into the
BglII/HindIII site of pTRE-GFP shuttle vector to gener-
ate pTRE-gBax. The pTRE-BC, -gBax, Bfl-1 and -GFP
constructs were linearized by PI-SceI and I-CeuI diges-
tion, inserted into adenoviral vector pAdenoX (Clon-
tech), digested with PacI, and then transfected into 293
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days after transfection, when the cytopathic effect
became evident, clear culture supernatants were
obtained, and viruses were then propagated in 293 cells
and purified by standard methods [30].
We used the Tet-off system to regulate gene expres-
sion, which responds equally well to either tetracycline
or doxycycline [31,32]. Briefly, both BC and Tet-off ade-
novirus were simultaneously infected into cells, in which
BC expression was inhibited in the presence of doxycy-
cline, but induced in its absence. The efficiency of the
Tet-off system was tested by examining GFP expression
and cell viability. Cells were cultured in 24-well plates at
a density of 1 × 10
5 per well. 24 h after plating, variable
concentrations of Tet-off and control or BC viruses
were added. Immediately after infection, doxycycline
(Sigma-Aldrich, St Louis, MO) was added to a final con-
centration of 1 mg/ml. Multiplicity of infection (MOI)
was determined by measuring the absorbance of disso-
ciated viruses at 260 nm; one absorbance was arbitrarily
s e ta t1 0
12 viral particles per milliliter. The particle-to-
infectious unit ratio was 100:1.
Cell viability, apoptosis, and cytochrome C release assays
The viabilities of treated cells were measured using a
Cell Counting Kit (CCK)-8 (Dojindo Molecular Tech-
nologies, Kumamoto, Japan). All assays were performed
in triplicate. For subG1 analysis, cells were harvested,
washed, and fixed overnight with 70% ethanol. Cell pel-
lets were re-suspended in staining buffer (10 μg/mL pro-
pidium iodide and 0.2 mg/mL RNase A in PBS), and
analyzed by flow cytometry (Epics XL; Coulter, Mar-
seille, France). Apoptotic cell death was determined by
Annexin V and/or PI staining followed by flow cytome-
try using Annexin V-FITC (or PE) kits (BD Pharmingen,
San Diego, CA). For DNA fragmentation analysis, geno-
mic DNA was extracted, subjected to electrophoresis in
2% agarose gel, and visualized by ethidium bromide
staining.
To measure cytochrome C release from mitochondria,
cells were harvested and fixed with 2% paraformalde-
hyde for 10 min at 37°C and then permeabilized with
buffer (1% BSA, 0.1% saponine, 0.1% sodium azide in
PBS) for 1 h on ice. Cells were stained with anti-cyto-
chrome C antibody (clone 6H2.B4) (BD Pharmingen)
and then with PE-labeled secondary antibody (Silenus,
Hawthorn, Australia), and analyzed by flow cytometry
[33].
Caspase activity assay
Cells were harvested, and then centrifuged at 450 g for
10 min at 4°C. After removing supernatant, cell pellets
were resuspended in 100 μlo fl y s i sb u f f e r( 5 0m M
HEPES pH 7.5, 1 mM DTT, 0.1 mM EDTA, 0.1%
CHAPS), and lysed by repeated freezing at -70°C and
thawing on ice. Cell lysates were cleared by centrifuga-
tion at 15,000 g for 20 min at 4°C; the resulting super-
natants are referred to as cell extracts. Typically, 100 μg
of cell extract was added to caspase activity assay buffer
(100 mM HEPES pH 7.5, 10% sucrose, 0.1% CHAPS, 10
mM DTT, 200 μM DEVD-pNA) with or without 100
μM Boc-D. These mixtures were then incubated at 37°C
for 4 h and the yellowish color caused by the release of
pNA was quantified using an ELISA reader at 405 nm.
Active caspase-3 levels were quantified using active cas-
pase-3-PE staining kits (BD Pharmingen) by flow
cytometry.
Immunoblotting
Cells were harvested and centrifuged at 500 g for 10
min at 4°C. The cell pellets were lysed with 2× sample
buffer (20 mM Tris pH 8.0, 2 mM EDTA, 2% SDS, 20
mM DTT, 1 mM Na3VO4, 20% glycerol). Cell lysates
were boiled for 3 min, and suspensions were centrifuged
at 10,000 g for 10 min at 4°C. The supernatants
obtained are referred to as whole cell lysates. Typically,
50 μg of total cellular proteins were separated by SDS-
PAGE and then transferred to a nitrocellulose mem-
brane, which was subsequently subjected to immuno-
blotting using the following antibodies; rabbit anti-Bcl-2,
-Bcl-xL,- B a x ,- N F - B p65/relA, and -lamin B (Santa
C r u zB i o t e c h n o l o g y ,S a n t aC r u z ,C A ) ,a n dm o u s ea n t i -
a-tubulin (Calbiochem, San Diego, CA). Rabbit polyclo-
nal antibody against human Bfl-1 was produced by a
commercial antibody production service (Youngin Fron-
tier, Seoul, Korea).
Reverse transcription-PCR (RT-PCR)
Total RNA was isolated from cells using TRIzol reagent
(Invitrogen). 5 μg aliquots of total RNA were subjected
to reverse transcription using a RT-PCR kit (Promega,
Madison, WI). cDNAs were amplified using primers as
follows; Bfl-1, forward 5’-GCTCAAGACTTTGCTCTC
CACC-3’ and reverse 5’-TGGAGTGTCCTTTCTGGT
CAACAG-3’;B c l - x L,f o r w a r d5 ’-GGATGGCCACT
TACCTGA-3’ and reverse 5’-CGGTTGAAGCGTTC
CTG-3’;B c l - 2 ,f o r w a r d5 ’-GTGTGGAGAGCGTCA
ACC-3’ and reverse 5’-GCTGGGGCCGTACAGTT-3’;
b-actin, forward 5’-GGAAATCGTGCGTGACATTA
AGG-3’ and reverse 5’-GGCTTTTAGGATGGCAAGG
GAC-3’.
NF-B activity assessment
NF-B activity was assessed by detecting the nuclear
translocation of NF-B subunit or luciferase assay. To
prepare nuclear extracts, cells were washed in ice cold
PBS and resuspended in Buffer A (10 mM HEPES
(pH7.9), 1.5 mM MgCl2, 10 mM KCl, 0.1 mM EDTA, 1
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incubation for 20 min on ice, nuclear pellets were recov-
ered by centrifugation at 1200 g, and suspended in Buf-
fer B (20 mM HEPES, 0.4 M NaCl, 1 mM EDTA, 1 mM
DTT, 25% glycerol). Aliquots were then incubated at 4°
C for 30 min and supernatants containing nuclear pro-
teins were collected by centrifugation at 21000 g. The
presence of NF-B subunits in nuclear and cytosolic
fractions was examined by immunoblotting using anti-
p64/RelA antibodies.
For luciferase assay, cells were transiently transfected
with pNF-B-Luc or pb-gal-lacZ plasmids using Lipo-
fectamine 2000 (Invitrogen, Carlsbad, CA). Luciferase
and b-galactosidase activities were measured using an
Orion luminometer (Berthold Detection Systems. Oak
Ridge, TN), and cellular protein contents were deter-
mined using the bicinchoninic acid technique (Pierce
Biotechnology Inc, Rockford, IL). Luciferase activities
were normalized versus lysate protein contents and b-
galactosidase activity used as an internal control to
determine transduction efficiency.
RNA interference
Three types of siRNAs were synthesized by Bioneer
(Daejon, Korea) to silence Bf l - 1 ,a sf o l l o w s :s i R N A 1 ,
sense 5’-AAGGAGUUUGAAGACGGCAUC-3’ and anti-
sense 3’-GAUGCCGUCUUCAAACUCCUU-5’ [25];
siRNA2, sense 5’-CCUAAAUCUGGCUGGAUGACU-3’
and anti-sense 3’-AGUCAUCCAGCCAGAUUUAGG-5’;
siRNA3, sense 5’-GCUAUCUCUCCUGAAGCAAUA-
CUGUUGA-3’ and anti-sense 3’-UCAACAGUAUUG-
CUUCAGGAGAGAUAGC-5’. The sequences of the
scrambled siRNAs used were sense: 5’-AAGGUCACA-
GAUAGAUUGGC-3’ and anti-sense 3’-GCCAAU-
CUAUCUGUGACCTT-3’. Transfection was performed
in 6-well plates at 70% confluence at a final siRNA con-
centration of 10 nM over 72 h using Lipofectamine
2000 (Invitrogen).
Animal experiments
To evaluate the in vivo anti-tumor effect of combined
BC and low dose gemcitabine therapy, we established a
tumor xenograft model in nude mice. Nude mice (6 to
8-week-old; Charles River Japan Inc., Yokohama) were
subcutaneously injected in the flank with 2×10
6 A549
cells in 100 μl PBS. When tumor volumes reached 5 to
10 mm in diameter, mice were randomly divided into
four groups with 5 animals per group. Tumor-bearing
mice were injected intratumorally with control (GFP) or
BC adenovirus and Tet-off-adenovirus at the same con-
centrations (5×10
8 PFU in 50 μl of PBS), and intraperi-
toneally administered with PBS or 10 mg/kg
gemcitabine. In brief, four experimental groups were
treated as follows: group 1, with control adenovirus and
PBS; group 2, control adenovirus and gemcitabine;
group 3, BC adenovirus and PBS; group 4, BC adeno-
virus and gemcitabine. These co-treatments were per-
formed three times with three days intervals. Tumor
growths were evaluated twice or three times weekly for
4 weeks after the last treatment by measuring the length
and width of each tumor using a caliper. Tumor
volumes were calculated using m1
2 ×m 2 × 0.5236
(where m1 and m2 are the short and long tumor axes).
Tumor weights were obtained using an analytical
balance.
Experiments and maintenance of mice were performed
according to the animal experiment guidelines at the
Center for Animal Resource Development (ethical com-
mittee), Seoul National University College of Medicine.
Statistical analysis
Data were analyzed using the Student’s t test, and p
values less than 0.05 were considered to be statistically
significant.
Results
Low dose gemcitabine treatment leads to NF-B
activation and Bfl-1 up-regulation in lung cancer cells
Initially, we examined the sensitivity of NSCLC cell lines
(A549, H157, PC9 and H460) to gemcitabine using
CCK-8 assays and subG1 analysis after incubating cells
with 0, 0.4, 4, 40, 400, or 4000 ng/ml of gemcitabine for
72 h. High dose (4000 ng/ml) gemcitabine reduced cell
viabilities by up to 50% and increased subG1 fractions
to about 50%; however, low dose (4 to 40 ng/ml) gemci-
tabine decreased cell viability by only ≤ 10% and subG1
fractions to about 20% (Figures 1A and 1B), indicating
that these lung cancer cells are relatively resistant to
low dose gemcitabine.
Because Bcl-2 family members play a role in determin-
ing the sensitivity of cancer cells to gemcitabine [34,35],
we examined the expressions of anti-apoptotic Bcl-2,
Bcl-xL,a n dB f l - 1b yR T - P C R .A ss h o w ni nF i g u r e1 C ,
low dose gemcitabine markedly up-regulated Bfl-1 with
little effect on Bcl-2 and Bcl-xL.A tt h ec o n c e n t r a t i o no f
4000 ng/ml gemcitabine, where cell viability was mark-
edly reduced, the Bfl-1 expression was decreased to the
basal level in all cell lines except for H460 cells. Real-
time RT-PCR analysis also demonstrated that low-dose
gemcitabine led to up-regulation of Bfl-1 with no
changes on the level of Bcl-2, Bcl-xL and Mcl-1 (Addi-
tional File 1, Figure S1).
NF-B activation is associated with gemcitabine resis-
tance, and Bfl-1 is a direct transcriptional target of NF-
B [36]. Therefore, to determine whether NF-Bi s
involved in the above-mentioned gemcitabine-induced
up-regulation of Bfl-1, we evaluated NF-B activities in
A549 and H157 cells using luciferase assay. NF-B
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Page 4 of 16Figure 1 Low dose gemcitabine cannot efficiently induce cell death in lung cancer cells, and leads to NF-B activation and Bfl-1
overexpression. A and B, A549, H157, PC9 and H460 cells were treated with 0, 0.4, 4, 40, 400, or 4000 ng/ml of gemcitabine for 72 h. Cell
viabilities were determined using CCK-8 assays (A), and subG1 populations were quantified by PI staining and flow cytometry (B). The values
shown are mean percentages of cells relative to untreated cells in three independent experiments performed in triplicate; error bars represent
SDs. C, A549, H157, PC9 and H460 cells were incubated in the presence of 0, 4, 40, 400, or 4000 ng/ml of gemcitabine for 24 h. Total RNAs were
extracted and the mRNA levels of Bfl-1, Bcl-xL, Bcl-2, and b-actin were determined by RT-PCR. D, A549 and H157 cells were transiently
transfected with pNF-B-Luc (firefly) plasmid for 16 h, and subsequently treated with 0, 4, 40, 400, or 4000 ng/ml of gemcitabine for an
additional 6 h. Cell were then lysed and analyzed for firefly luciferase activity. Data are mean luciferase activities normalized versus b-gal
expression obtained from three independent experiments; error bars represent SDs. Results are presented as means ± SDs of three independent
experiments performed in triplicate. *p < 0.001 by the Student’s t test for difference in tumor volumes between experimental groups.
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Page 5 of 16activities were elevated by gemcitabine treatment at 4 to
400 ng/ml for 6 h (Figure 1D), which were relatively
well correlated with the transcriptional induction of Bfl-
1, as shown in Figure 1C. Of note, at a concentration of
4000 ng/ml which efficiently compromised cell viability
(Figures 1A and 1B), NF-B activity was returned to the
basal level, which was consistent with the change of Bfl-
1 expression (Figures 1C and 1D). These data suggest
that lung cancer cells resist low dose gemcitabine via
NF-B activation and subsequent Bfl-1 overexpression.
The borderline dose of 400 ng/ml gemcitabine induces
a decrease of cell viability whereas Bfl-1 and NF-kB are
up-regulated. This discrepancy might result from the
different time points of assays for each factor; namely,
luciferase assay for NF-kB activity at 6 h after gemcita-
bine treatment, RNA extraction for Bfl-1 RT-PCR at 24
h, and CCK-8 assay for cell viability at 72 h. DNA
damage caused by gemcitabine 400 ng/ml functions as a
form of stress and can lead to the activation of NF-kB
within 12 h [37]. However, in spite of initial activation
of NF-kB, gemcitabine exerts delayed cytotoxic effects
which can take longer than 72 h [38,39]
The C-terminal region of Bfl-1 fused with GFP (BC)
induced caspase-mediated apoptosis in lung cancer cells
We previously reported that a protein containing the C-
terminal region of anti-apoptotic Bfl-1 and GFP is able
to efficiently induce apoptosis in 293T cells [17,29]. In
the present study, we utilized an adenoviral system for
BC gene therapy in lung cancer cells and a Tet-induci-
ble system, as described in Materials and Methods. Initi-
ally, we examined whether BC delivered via adenoviral
vector could induce lung cancer cell apoptosis. Three
days after infection, cell viabilities were assessed by
fluorescence microscopy and CCK-8 assays. When A549
and H157 cells were co-infected with control (GFP) and
Tet-off adenoviruses, more than 90% of the cells emitted
green fluorescence, which suggested successful gene
delivery by the adenovirus. Furthermore, whereas the
control vector showed little cytotoxicity, the BC contain-
ing vector suppressed cell viability and induced cell
death (Figures 2A and 2B). This cell death was thought
to be apoptotic in nature, as indicated by the appearance
of active caspase 3 and DNA laddering (Figures 2C, D
and 2E). These findings indicate that BC is able to
induce the apoptosis of lung cancer cells.
BC restored lung cancer cell sensitivity to low dose
gemcitabine
Next, we investigated whether BC could sensitize lung
cancer cells to low dose gemcitabine. Commonly
annexin V-FITC (green)/PI (red) is used to confirm
apoptosis. However in this particular situation, the fluor-
escence emitted from GFP and FITC are both green and
cannot be distinguished from each other. Therefore,
instead of using annexin V-FITC, we used annexin-PE
to obtain Figure 3C, and showed Annexin V/GFP + gat-
ing cells numbers in percentage by histogram. Whereas
low dose (0.4 to 40 ng/ml) gemcitabine treatment for 72
h led to subG1 arrest in only 10-20% of A549 cells and
BC monotherapy induced subG1 arrest in about 40% of
cells, combined treatment with BC and low dose gemci-
tabine increased the subG1 population to 70-100% (Fig-
u r e3 A ) .C y t o c h r o m eCr e l e a s ea s s a y sa n da n n e x i nV
staining also demonstrated that BC and low dose (40
ng/ml) gemcitabine acted additively or synergistically to
cause mitochondria-mediated apoptosis in A549 and
H157 cells (Figure 3B and 3C).
Because Bax gene therapy is widely used to induce
chemosensitization and promote tumor cell apoptosis by
disrupting mitochondrial membrane integrity [37], we
compared the efficacies of BC and Bax gene therapies in
combination with gemcitabine. As determined by subG1
analysis, BC was superior to Bax in sensitizing A549
cells to gemcitabine (p < 0.001)( F i g u r e3 Da n dF i g u r e
Additional File 2, Figure S2). In addition, the C-terminal
region of Bfl-1-fused with external charged residues
from potential efficiency vector sequence (not GFP)
(MBC) also showed proapoptotic function and sensitized
A549 cells to gemcitabine (Figure 3E). Collectively, these
findings suggest that A549 cells could be sensitized to
low dose gemcitabine by co-administering BC via its
additive or synergistic cytotoxic effect.
BC suppressed NF-B activity and down-regulated Bfl-1
expression, thereby sensitizing lung cancer cells to
gemcitabine
Figure 1 and Figure Additional file 1, Figure S1 showed
that low dose gemcitabine activated NF-Ba n du p -
regulated Bfl-1 expression in lung cancer cells, which
might be one of the underlying resistant mechanisms to
low dose gemcitabine. Above observation that BC sensi-
tized lung cancer cells to gemcitabine led us to investi-
gate the effects of BC on NF-B activity and Bfl-1
expression. As shown in Figure 4A, low dose (40 ng/ml)
gemcitabine-induced Bfl-1 overexpression was inhibited
by BC co-treatment in A549 cells. Bfl-1 protein expres-
sion was also suppressed by BC (Figure 4B). BC also
down-regulated the Bcl- xL but increased the Bax
expression (Figure 4B). These data suggested that BC
might alter the balance of Bcl-2 family proteins towards
the pro-apoptotic state, which includes down-regulation
of Bfl-1. We next assessed the effect of BC on NF-B
activity in A549 cells. BC treatment was found to reduce
NF-B activity to half its basal level; furthermore, NF-
B activity, which had been elevated by more than 3-
fold by gemcitabine at 40 ng/ml, markedly declined to a
very low level when cells were co-treated with BC and
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Page 6 of 16Figure 2 C-terminal of Bfl-1 fused with GFP (BC) inhibits proliferation and induces lung cancer cell apoptosis. A and B, A549 and H157
cells were infected with 10 MOI of the C-terminal of Bfl-1-GFP (BC) or control-GFP (Con) adenovirus and Tet-off adenovirus, and maintained with
or without doxycycline for 72 h. In these environments, the expression of BC or GFP was inhibited in the presence of doxycycline and induced
in its absence. Cell viabilities were determined using CCK-8 assays, and are expressed the mean percentages of control adenovirus infected cells
as determined by three independent experiments. Error bars represent SDs (A). Cellular morphologies were examined by fluorescence
microscopy (B). C, D and E, A549 cells were transfected with BC or Con and Tet-off adenoviruses, and cultured in the absence of doxycycline for
72 h. Active caspase-3 levels were measured by flow cytometry using PE-conjugated anti-active caspase-3 antibody (C). After infecting cells for
48 h, they were lysed and 100 μg of whole cell lysates were treated with caspase activity assay buffer containing the peptide caspase substrate
DEVD-pNA, for 4 h. Results are the average absorbance at 405 nm of experiments conducted in triplicate, and error bars represent SDs (D). After
infecting cells for 72 h, total genomic DNA was extracted and subjected to electrophoresis in 2% agarose gel to examine DNA fragmentation
patterns (E).
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Page 7 of 16Figure 3 BC sensitizes lung cancer cells to low dose gemcitabine. A, A549 cells infected with BC (filled bars) or control (Con, hatched bars)
adenovirus were treated with 0, 0.4, 4, 40, or 400 ng/ml of gemcitabine for 72 h. Cell deaths were determined by subG1 analysis. Open bars
represent non-infected A549 cells. The graph was plotted using the means ± SDs of three experiments. *p < 0.001 by the Student’s t test for
difference in tumor volumes between experimental groups. B and C, A549 and H157 cells infected with BC or control adenovirus were cultured
with or without 40 ng/ml gemcitabine for 72 h. Cells were analyzed by flow cytometry for cytochrome C release (B). Apoptotic cell death was
determined by FACS analysis of annexin V-PE stained cells among GFP expressing cells. Representative data (upper) and means ± SDs of three
experiments (lower) are shown. * p < 0.001 by the Student’s t test for differences between amounts of annexin V-PE (+) cells by gemcitabine in
control and BC infected cells (C). D, A549 cells infected with BC (filled bars: BC only effect) or Bax (hatched bars) adenovirus were maintained in
the presence or absence of 40 ng/ml gemcitabine for 72 h. SubG1 fractions were quantified by PI staining and FACS. Representative data
(upper) and the means ± SDs of three experiments (lower) are shown. * p < 0.001 by the Student’s t test for differences between amounts of
subG1 fraction increases induced by gemcitabine in BC and Bax infected cells. E, A549 cells were transfected with pcDNA, pcDNA-MBC(no
tagging GFP), or pcDNA-BAX; 24 hours later, the cells were stained with annexinV-FITC and PI, and cell death was analyzed by flow cytometry.
Annexin V-FITC positive cell (without/with-gem), pCDNA: 0.8/1.4(%), MBC: 13.4/20.8(%) and BAX: 22.4/30.6(%). PI positive cell (without/with-gem):
pCDNA: 1.7/3.5(%), MBC:13.8/13.7(%) and BAX:11.4/9.4(%). Annexin V-FITC/PI double positive cell (without/with-gem): pCDNA: 0.1/0.3(%), MBC:
11.4/41.7(%) and BAX: 8.3/10.5(%).
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Page 8 of 16Figure 4 BC down-regulates Bfl-1 expression by inhibiting NF-B activity. A, A549 cells infected by BC or control (Con) adenovirus were
treated with 40 ng/ml gemcitabine for 72 h. Total RNA was isolated and subjected to RT-PCR for Bfl-1 and b-actin. B, A549 cells were infected
with BC or control adenovirus and treated with 40 ng/ml gemcitabine or not. 50 μg of total cellular proteins were subjected to SDS-PAGE and
then immunoblotted using anti-Bfl-1, -Bax, -Bcl-xL, -Bcl-2, and -a-tubulin antibodies. Data are representative of three independent experiments. C,
A549 cells, transfected with the pNF-B-Luc reporter gene and b-gal-lacZ plasmid, were infected with BC or control adenovirus and then treated
with 40 or 400 ng/ml of gemcitabine for 48 h. Luciferase and b-galactosidase activities were determined using a luminometer. The values shown
represent luciferase activities relative to b-gal, and the means ± SDs from three independent experiments are plotted. *p < 0.001 by the
Student’s t test for difference in tumor volumes between experimental groups. D, A549 cells infected with BC or control adenovirus were treated
with 0, 40, or 400 ng/ml gemcitabine for 48 h. Proteins from nuclear and cytosolic fractions were separately isolated, and 50 μg aliquots were
subjected to SDS-PAGE and then immunoblotted using anti-p65/relA, -lamin B, and -a-tubulin antibodies. Data are representative of three
independent experiments.
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Page 9 of 16gemcitabine (40 ng/ml) (Figure 4C). Immunoblotting
also revealed that low dose gemcitabine caused the
translocation of p65/relA from the cytoplasm to the
nucleus, which was prevented by BC (Figure 4D). These
findings together suggest that BC might suppress NF-B
activity and subsequently down-regulate Bfl-1, and thus,
sensitizes lung cancer cells to gemcitabine-induced cell
death.
However, it still remained unclear whether the BC-
induced down-regulation of Bfl-1 caused the observed
sensitization to gemcitabine or just was a coincidence.
To address this, we examined whether the direct sup-
pression of Bfl-1 by siRNA could sensitize A549 cells to
gemcitabine-induced apoptosis. It was found that
whereas the direct down-regulation of Bfl-1 had little
effect on cell viability, Bfl-1 siRNA and gemcitabine co-
treatment increased apoptotic cell death (Figures 5A
and 5B). These data suggest that Bfl-1 might play a role
in gemcitabine resistance of lung cancer cells, and that
the down-regulation of Bfl-1, either directly or using
BC, offers an effective means of making lung cancer
cells sensitive to gemcitabine.
BC and low dose gemcitabine co-treatment efficiently
suppressed tumor growth and induced tumor cell death
in a lung cancer xenograft model
Finally, to evaluate the in vivo anti-tumor effect of BC
and low dose gemcitabine therapy, we established a
human lung cancer xenograft model in nude mice using
A549 cells as described in Materials and Methods. As
shown in Figure 6, in mice treated with control adeno-
virus or gemcitabine, tumors reached mean volume of
2488 mm
3 ± 1282 mm
3 at 30 days after the last treat-
ment. However, tumor growth was significantly inhib-
ited in mice co-treated with BC and gemcitabine; the
average tumor volume was 380 ± 97 mm
3 at 30 days (a
reduction of 85% versus control mice treated with ade-
novirus and PBS), which consistent with more than an
80% reduction in tumor weight (Figures 6A and 6B).
Histologic examination of tumors revealed more exten-
sive necrosis and frequent apoptotic cells with nuclear
condensation and fragmentation in mice co-treated with
BC and gemcitabine than in control mice or those trea-
ted with gemcitabine only (Figure 6C and Additional
File 3, Figure S3). These findings suggest that co-treat-
ment with BC and low dose gemcitabine could effi-
ciently suppress tumor growth and induced tumor cell
death in vivo.
Discussion
Gemcitabine has been previously shown to be effective
in NSCLC, but acquired resistance after prolonged and
repeated exposure was found to reduce response rates
in clinical trials [7,40]. Moreover, because high
therapeutic doses of gemcitabine cause bone marrow
suppression and reduce general health status, optimal
dosages and medication schedules are required to
achieve tumor control and improve quality of life [41].
For example, low doses of gemcitabine could be con-
tinuously administered by infusion-based to patients
with locally advanced disseminated cancer, because of
its lower toxicity than the standard gemcitabine regimen
[42]. However, chemotherapeutic stresses elicited by low
concentrations of gemcitabine lead to NF-B activation
and enhance Akt signaling, and thereby cause drug
resistance [43]. Otherwise, in practice, to overcome low
response rates in NSCLC, gemcitabine is used in combi-
nation with other cytostatic agents with different modes
of action [44]. Therefore, it is conceivable that combina-
tional approaches based on gene therapy targeting the
drug resistance pathway and gemcitabine, as shown by
the present study, might have a merit for tumor control.
NF-B activation status of cancer cells can be repre-
sented by its basal level or chemotherapy-induced up-
regulation of NF-B activity. Which of them is more
important for chemoresistance in cancer remains con-
troversial [45]. In previous reports, NF-B activity was
high at the basal level, and was also elevated by gemcita-
bine treatment in pancreatic cancer, breast cancer, and
NSCLC. NF-B activation and the subsequent up-regu-
lations of NF-B-regulated genes have been suggested
to attenuate the efficiency of gemcitabine. In fact, sev-
eral studies have reported that the suppression of NF-
B activity can sensitize cancer cells to gemcitabine
[5,6,18]. On the other hand, Pan et al. recently reported
that there was no significant correlation between basal
NF-B activity and gemcitabine sensitivity, and that
gemcitabine did not activate NF-B in pancreatic cancer
cells [5]. Furthermore, silencing of p65/relA increased
apoptosis in gemcitabine-sensitive pancreatic cancer
cells, but not in resistant cells [19]. These conflicting
observations suggest that the association between gemci-
tabine efficacy and NF-B activity might not be identical
among cancers, but should be considered in a cell type-
specific manner.
In agreement with previous studies by Denlinger et al.
using NSCLC cell lines (A549 and H157) [18], we
observed that low dose gemcitabine enhanced NF-B
activity in A549 and H157 cells. In line with the gemci-
tabine-induced NF-B activation, its target gene Bfl-1
was found to be markedly up-regulated, with little effect
on the levels of other anti-apoptotic Bcl-2 proteins,
including Bcl-2 and Bcl-xL; furthermore, this was
observed in all NSCLC cell lines examined. Bfl-1overex-
pression has been reported to underlie resistance to var-
ious apoptotic stimuli [23], and we previously observed
that Bfl-1 is frequently over-expressed in lung cancer
cell lines [28]. Therefore, we speculated that Bfl-1 might
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Page 10 of 16Figure 5 Bfl-1 siRNA sensitized lung cancer cells to low dose gemcitabine. A, A549 cells were transfected with three types of Bfl-1 siRNA
and then treated with 40 ng/ml gemcitabine for 48 h. Cells were then stained with Annexin V-FITC/PI and analyzed by flow cytometry.
Experiments were performed three times and yielded comparable results. B, Total protein and RNA were extracted from A549 cells transfected
with three types of Bfl-1 siRNA. 50 μg of total cellular proteins were subjected to SDS-PAGE and then immunoblotted using anti-Bfl-1 and -a-
tubulin antibodies (upper panel), and RNAs were subjected to RT-PCR to determine Bfl-1 expression. b-actin was used as an internal control
(lower panel).
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Page 11 of 16Figure 6 Combined BC and low dose gemcitabine therapy efficiently suppressed tumor growth and induced tumor cell death in a
lung cancer xenograft model. A, A549 cells (2×10
6) were injected into the flank of 6- to 8-week-old male nude mice to establish a tumor
xenograft model. Three weeks later when tumor volumes had reached about 100 mm
3, BC or control adenovirus and Tet-off adenovirus (5×10
6
PFU) were directly injected into tumors, and 10 mg/kg gemcitabine or PBS were administered intraperitoneally. These therapies were performed
three times with two days intervals. Tumor volumes were measured every 2 to 3 days for one month. Each experimental group included 5 mice
and means ± SDs are plotted. *p < 0.001 and ** p < 0.05 by the Student’s t test for differences between tumor volumes between experimental
groups. B and C, On day 30 after the last treatment, mice were sacrificed and tumors were extracted. The histogram shows the means ± SDs of
tumor weights in each group (n = 5) (B). Tumor sections were analyzed by hematoxylin and eosin staining for histological features, such as,
tumor necrosis and apoptosis. Numbers at the top of column indicates magnification (C).
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Page 12 of 16regulate the sensitivity of NSCLC to gemcitabine. As
was expected, direct Bfl-1 suppression using siRNA sen-
sitized cells to gemcitabine-induced apoptosis in A549
cells. In a study conducted by Brien et al. in B lympho-
blastoid and diffuse large B-cell lymphoma cell lines,
Bfl-1 silencing was found to potently induce apoptosis,
and sensitize cells to rituximab-mediated cell death and
apoptosis by doxorubicin, vincristine, cisplatin, or flu-
darabine [25]. In the present study using lung cancer
cell lines, although siRNA-mediated Bfl-1 suppression
per se did not affect cell viability, it sensitized cells to
gemcitabine. Therefore, the present and our previous
findings suggest that Bfl-1 is a feasible molecular target
for enhancing the efficacy of gemcitabine in lung cancer.
Furthermore, in view of the fact that BC itself alone has
a cytotoxic effect, it would appear that BC is likely to be
better than siRNA at chemosensitizing cells. Although
previous studies have reported that NF-B regulates the
expression of Bcl-xL and/or Bcl-2 in various cell types
[46], we observe little changes in the level of Bcl-xL and
Bcl-2 in cells treated with gemcitabine at low concentra-
tions inducing NF-B activation either by RT-PCR and
real-time RT-PCR. It is possible that Bfl-1, a direct tar-
get of NF–B, might function as an important and sen-
sitive anti-apoptotic Bcl-2 family protein reflecting the
alteration of NF–B activity in NSCLC cells, particularly
in terms of response to gemcitabine.
Although Bfl-1 is an anti-apoptotic bcl-2 family mem-
ber and primarily prevents apoptosis, its protective effect
depends on cell type and apoptotic stimulus [26,27,47].
Furthermore, Bfl-1 can be converted into a pro-apopto-
tic molecule when processed by proteasome or TNF
receptor signaling in pro-B cells [27,47]. In this system,
the Bfl-1 C-terminal domain was important for the pro-
apoptotic function of Bfl-1, because it was required for
Bfl-1 ubiquitination and its localization at the mitochon-
drial membrane[29]. Our group, previously, demon-
strated that anti-apoptotic Bfl-1 is converted to a pro-
apoptotic protein when fused with GFP, and that the 29
amino acids of its C-terminal region are sufficient to
induce apoptotic cell death via the mitochondrial path-
way and caspase activation in 293T cells [17,29,48]. An
amphipathic tail-anchoring domain of the Bfl-1 C-term-
inal region has been implicated in the targeting of Bfl-1
to the mitochondrial membrane to induce apoptosis
[17,27,47]. These findings led us to hypothesize that the
Bfl-1 C-terminal region fused with GFP (BC) could be
harnessed as a gene therapy in combination with che-
motherapeutic agents to achieve management of cancer.
Previously, we used a plasmid vector system to deliver
BC to 293T cells to investigate its apoptotic effects.
However, BC-plasmid showed a little cytotoxicity in
A 5 4 9c e l l sa sc o m p a r e di n2 9 3 Tc e l l s ,w h i c hw a sc o n -
sidered to be due to low transfection efficiencies in the
cancer cell lines examined. Therefore, in the present
study, we utilized an adenoviral system to examine the
possibilities of BC gene therapy. Accordingly, we gener-
ated a replication-deficient adenovirus expressing BC,
GFP only (Control), or Bax-GFP, and employed a Tet-
inducible system. As was expected, transfection of BC
using this adenoviral system efficiently induced apopto-
sis in A549 and H157 cells. Moreover, we found that
BC remarkably suppressed NF-B activity. Although
transfection with pro-apoptotic Bax induced cell death
at higher levels than BC alone, BC sensitized cells to
gemcitabine more than Bax, which we attribute to the
NF-B suppressing effect of BC. Taken together, we
consider that BC inhibits NF-Ba n ds u b s e q u e n t l y
down-regulates Bfl-1, thereby sensitizing cells to gemci-
tabine-induced apoptosis in an additive or synergistic
manner. We also found that co-treatment with BC
delivered by adenovirus using a Tet-inducible system in
combination with low dose gemcitabine efficiently inhib-
ited tumor growth and induced tumor cell apoptosis
and necrosis with little systemic toxicity in a xenograft
mouse model. These results cautiously raise the possibi-
lity that BC gene therapy could be used to lower gemci-
tabine doses in order to control cancer and avoid toxic
side effects. Because its intrinsic cytotoxic effect of BC,
we were cautious to reach a conclusion that BC sensi-
tized lung cancer cells to gemcitabine-induced cell death
in a synergistic rather than just additive manner.
Although the results of apoptosis assay by FACS (Figure
3C) showed an additive cytotoxic effect of BC and gem-
citabine rather than synergistic, subG1 analysis (Figure
3D) and in vivo tumor suppressive effect (Figure 6A) of
BC and gemcitabine was synergistic rather than additive.
The way how BC suppresses NF-B activity remains
to be elucidated, and if BC could directly down-regu-
lated Bfl-1 by mechanisms other than inhibition of NF-
B is open to further study. We currently just have
some speculations on this subject. One of them is that
because Bfl-1 is constitutively ubiquitinized at its C-
terminal region and processed by proteasomal degrada-
tion, BC might function as a kind of competitive inhibi-
tor of proteasome, thereby leading to NF-B
suppression and cell death. We have a clue that p53
pathway might be involving; we have observed that BC
causes NF-B inhibition through p53 activation (data
not shown). However, more precise mechanism should
be clarified by further study.
BC and low dose gemcitabine also showed synergistic
cytotoxic effects in the MDA-MB-231 and MCF7 breast
cancer cell lines (Additional file 4, Figures S4A and B).
Furthermore, to test if BC can overcome resistance to
high dose gemcitabine, we established acquired gemcita-
bine resistant cell lines, A549GR, which resist gemcita-
bine up to 40000 ng/ml, and included intrinsic
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Page 13 of 16gemcitabine-resistant pancreas cancer cell lines, Panc1.
As shown in Additional file 4, Figure S4A, BC co-treat-
ment induced cell death in high dose gemcitabine-resis-
tant cells. We also observed that BC was able to
sensitize A549 and H157 cells to sublethal doses of eto-
poside, doxorubicin, or staurosporine again in an addi-
tive or synergistic manner (Additional File 4, Figure
S4C). These data suggests that BC gene therapy might
be used to overcome resistance to chemotherapeutic
agents other than gemcitabine in variable cancers. How-
ever, our main focuses were gemcitabine- NF-B -Bfl-1
axis implicated in low gemcitabine resistance of lung
cancer cells, and the utility of BC to overcome gemcita-
bine resistance in this system. Therefore we tried to
show the efficient of combined BC and gemcitabine
therapy and to dissect the underlying mechanism. If the
same axis of gemcitabine- NF-B -Bfl-1 regulation
would be working in the above mentioned additive or
synergistic cytotoxicity of BC in other system remains to
be clarified.
Summarizing, the present study demonstrates that
lung cancer cells resist low dose gemcitabine because
NF-B is activated by gemcitabine and Bfl-1 is subse-
quently up-regulated. BC transfection was found to sen-
sitize cells to gemcitabine by suppressing NF-Ba c t i v i t y
and Bfl-1; and moreover co-treatment by BC transfec-
tion and gemcitabine chemotherapy showed a strong
anti-tumor effect in vivo. Our findings indicate that tar-
geting the NF–B/Bfl-1 pathway with BC might be uti-
lized for improving the chemotherapeutic effects of
gemcitabine in lung cancer.
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Additional material
Additional file 1: Figure S1. Low dose gemcitabine markedly up-
regulated Bfl-1 mRNA level. Total RNA was isolated from cells using
TRIzol reagent (Invitrogen) according to the manufacturer’s instructions. 5
μg aliquots of total RNA were reversely transcribed to cDNAs using a RT-
PCR kit (Promega, Madison, WI). Then real-time PCR was carried out
using Power SYBR
®® Green PCR Master Mix (Applied Biosystems, Foster,
CA) with a Bio-Rad iCycler iQ system, and gene-specific primers as
follows; Bfl-1, forward 5’-CAGCACATTGAATCAACAGC-3’ and reverse 5’-
TGCAGATAGTCCTGAGCCAGC-3’; Bcl-xL, forward 5’-
GAGGCAGGCGACGAGTTTGAA-3’ and reverse 5’-
GGGGTGGGAGGGTAGAGTGGA-3’; Mcl-1, forward 5’-
AAGCCAATGGGCAGGTCT-3’ and reverse 5’-TGTCCAGTTTCCGAAGCAT-3’;
b-actin, forward 5’-GGAAATCGTGCGTGACATTAAGG-3’ and reverse 5’-
GGCTTTTAGGATGGCAAGGGAC-3’. Each sample was run in triplicate.
Relative transcript abundance was calculated using the comparative CT
method for a standard control b-actin. Thermal cycling conditions were
as follows: 95°C for 3 min, followed by 40 cycles of 95°C for 15 s and 55°
C for 30 s.
Additional file 2: Figure S2. BC was better in sensitizing lung cancer
cells to gemcitabine than Bax. A549 cells infected with BC or BAX
adenovirus were maintained in the presence or absence of 40 ng/ml
gemcitabine for 72 h. SubG1 fractions were quantified by PI staining and
FACS. GFP (%) represented infection efficiency of adenovirus constructs.
Additional file 3: Figure S3. Staining for Histological features.O n
day 30 after the last treatment, mice were sacrificed and tumors were
extracted. The histogram shows the means ± SDs of tumor weights in
each group (n = 5). Tumor sections were analyzed by hematoxylin and
eosin staining for histologic features, such as, tumor necrosis and
apoptosis. Numbers at the top of column indicates magnification.
Additional file 4: Figure S4. BC synergistically compromised cell
viability when administered with different chemotherapeutics to
cancer cell lines. Human breast cancer cell lines, MDA-MB-231 (ATCC
HTB-26, passage-8) and MCF7 (ATCC HTB-22, passage-13) and PANC-1
(ATCC CRL-1469, passage-5) cells were verified by morphology, growth
curve analysis and tested for Mycoplasma. All cell lines were obtained
from and characterized by the American Type Culture Collection (ATCC).
No further authentication was done by the authors. Etoposide,
doxorubicin and staurosporine were purchased from LC Laboratories
(Woburn, MA). A, MDA-MB-231 (MDA) and MCF7 (MCF) (human breast
cancer cell lines), A549, H460, PC9 (human lung adenocarcinoma cell
lines), and H157 (a human lung squamous cell carcinoma cell line) cells
infected by BC or control adenovirus and Tet-off adenovirus, and then
treated with 40 ng/ml gemcitabine for 72 h (upper panel). A549,
gemcitabine-resistant A549 cells (A549GR), and PANC-1 (an intrinsic
gemcitabine-resistant human pancreatic carcinoma cell line) were cells
were infected with BC or control adenovirus and Tet-off adenovirus, and
then treated with 0, 40, or 40000 ng/ml gemcitabine for 72 h (lower
panel). Gemcitabine-resistant A549 cells (A549GR) were generated by
exposure to increasing concentrations of gemcitabine from the first
concentration of 40 ng/ml to final selection concentration of 4μg/ml.
A549GR cells were passaged 4 to 5 times in the absence of drug about
for 2 weeks, and maintained in the final selection concentration. Cell
viabilities were measured using CCK-8 assays. Values are expressed as
mean percentages of untreated cells in three independent experiments
performed in triplicate; error bars represent SDs. B, A549, H157, H460 and
MDA-MB-231 cells infected by BC or control adenovirus and Tet-off
adenovirus treated with 40 ng/ml gemcitabine for 72 h. Cytochrome C
release was analyzed by flow cytometry. Values are expressed as mean
percentages of untreated cells in three independent experiments
performed in triplicate; error bars represent SDs. C, A549 and H157 cells
infected by BC or control adenovirus and Tet-off adenovirus were treated
with 40 ng/ml gemcitabine, 10 nM etoposide (eto), 10 nM doxorubicin
(dox), or 1 nM staurosporine (sts) for 72 h. Cell viabilities were
determined using CCK-8 assays and are expressed relative to numbers of
untreated cells. Results are presented as means ± SDs of three
independent experiments performed in triplicate. *p < 0.001 by the
Student’s t test for differences between tumor volumes between
experimental groups.
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